Lonza introduces a new and modern corporate identity to better reflect all that Lonza does. As a result of this re-branding initiative, the company will focus the external communication on the seven major markets it serves: BioResearch, Pharma & Biotech, Nutrition, Microbial Control, Agriculture, Materials Science and Personal Care.
Understanding the needs of the customers, Lonza business units will no longer communicate singly with the diverse customer base, but instead present a coordinated and unified approach, demonstrating all that Lonza can offer them, now and in the future.
A new Corporate Brochure, which combines all that Lonza has to offer into one consolidated piece, is now available. The piece provides an overview of Lonza’s offerings to the seven major markets we serve as well as a glimpse of our new visual approach. The brochure can be viewed and downloaded on lonza.com: www.lonza.com/group/en/company/about/our_markets.html
Other external materials, including the company’s website, are being recreated and redesigned to enhance communications between Lonza and its customers.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically.
Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing.
Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.